NO147243C - Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater

Info

Publication number
NO147243C
NO147243C NO770109A NO770109A NO147243C NO 147243 C NO147243 C NO 147243C NO 770109 A NO770109 A NO 770109A NO 770109 A NO770109 A NO 770109A NO 147243 C NO147243 C NO 147243C
Authority
NO
Norway
Prior art keywords
phtaland
derivatives
preparation
therapeutic active
analogy procedure
Prior art date
Application number
NO770109A
Other languages
English (en)
Other versions
NO770109L (no
NO147243B (no
Inventor
Klaus Peter Boegesoe
Anders Stausboell Toft
Original Assignee
Kefalas As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9722860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO147243(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kefalas As filed Critical Kefalas As
Publication of NO770109L publication Critical patent/NO770109L/no
Publication of NO147243B publication Critical patent/NO147243B/no
Publication of NO147243C publication Critical patent/NO147243C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO770109A 1976-01-14 1977-01-13 Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater NO147243C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1486/76A GB1526331A (en) 1976-01-14 1976-01-14 Phthalanes

Publications (3)

Publication Number Publication Date
NO770109L NO770109L (no) 1977-07-15
NO147243B NO147243B (no) 1982-11-22
NO147243C true NO147243C (no) 1983-03-02

Family

ID=9722860

Family Applications (2)

Application Number Title Priority Date Filing Date
NO770109A NO147243C (no) 1976-01-14 1977-01-13 Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater
NO1996001C NO1996001I1 (no) 1976-01-14 1996-01-05 Citalopram

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1996001C NO1996001I1 (no) 1976-01-14 1996-01-05 Citalopram

Country Status (19)

Country Link
US (1) US4136193A (no)
JP (1) JPS52105162A (no)
AT (1) AT359488B (no)
AU (1) AU509445B2 (no)
BE (1) BE850401A (no)
CA (1) CA1094087A (no)
CH (3) CH626886A5 (no)
DE (1) DE2657013C2 (no)
DK (1) DK143275C (no)
ES (1) ES454980A1 (no)
FI (1) FI63754C (no)
FR (1) FR2338271A1 (no)
GB (1) GB1526331A (no)
IE (1) IE44055B1 (no)
NL (2) NL192451C (no)
NO (2) NO147243C (no)
NZ (1) NZ183001A (no)
SE (1) SE429551B (no)
ZA (1) ZA7757B (no)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
DK0759299T3 (da) * 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
KR100357975B1 (ko) * 1997-07-08 2002-10-25 하. 룬트벡 아크티에 셀스카브 시탈로프램의 제조방법
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
DE1042310T1 (de) 1997-11-11 2001-04-19 Lundbeck & Co As H Verfahren zur herstellung von citaloprame
WO2000023431A1 (en) 1998-10-20 2000-04-27 H. Lundbeck A/S Method for the preparation of citalopram
HRP20010418A2 (en) 1998-12-08 2002-06-30 Lundbeck & Co As H Benzofuran derivatives, their preparation and use
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
PL203275B1 (pl) 1998-12-23 2009-09-30 Lundbeck & Co As H Sposób wytwarzania 5-cyjanoftalidu
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
PL198024B1 (pl) * 1999-04-14 2008-05-30 Lundbeck & Co As H Sposób wytwarzania citalopramu, związki pośrednie i ich zastosowanie do wytwarzania citalopramu
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991486A1 (it) * 1999-07-06 2001-01-06 Vis Farmaceutici S P A Processo per la sintesi di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
KR100505820B1 (ko) 1999-10-25 2005-08-03 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조방법
CH692421A5 (de) 1999-10-25 2002-06-14 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram.
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
US6310222B1 (en) * 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
KR20020073489A (ko) 1999-12-28 2002-09-26 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
JP2003519218A (ja) * 1999-12-30 2003-06-17 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
CZ20022601A3 (cs) * 2000-01-14 2002-10-16 H. Lundbeck A/S Způsob výroby 5-kyanoftalidu
US6433196B1 (en) * 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
IES20010143A2 (en) * 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
NL1017415C1 (nl) * 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
TR200202166T2 (tr) 2000-03-13 2002-12-23 H. Lndbeck A/S Sitalopramın preparasyon metodu
TR200202195T2 (tr) * 2000-03-13 2002-12-23 H. Lundbeck A/S 5-Yer değiştirmiş 1-(4-florofenil)-1,3- dihidroizobenzofuran'ın adım adım alkillenmesi
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001068630A1 (en) 2000-03-14 2001-09-20 H. Lundbeck A/S Method for the preparation of citalopram
ES2159271B1 (es) * 2000-03-16 2002-05-01 Lundbeck & Co As H Metodo para la preparacion de 5-ciano-1-(4-fluorofenil)-1,3-dihidroisobenzofuranos
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation A- (BETA) -42 DECREASING MEDICINAL PRODUCTS
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
KR100821912B1 (ko) * 2000-05-12 2008-04-16 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
BR0106976A (pt) * 2000-07-06 2002-07-23 Lundbeck & Co As H Método para a preparação de citalopram
JP2004504393A (ja) * 2000-07-21 2004-02-12 ハー・ルンドベック・アクチエゼルスカベット 新規化合物及びそのグリシントランスポート阻害剤としての使用方法
IES20010693A2 (en) * 2000-08-10 2002-07-10 Lundbeck & Co As H Pharmaceutical composition containing citalopram
CA2354880C (en) * 2000-08-18 2003-06-03 H. Lundbeck A/S Method for the preparation of citalopram
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
IT1319686B1 (it) * 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
IL147226A (en) * 2000-12-22 2006-04-10 Lundbeck & Co As H Process for the preparation of pure citalopram
DE10112828C1 (de) * 2000-12-28 2002-11-21 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
DE10164725B4 (de) * 2000-12-28 2004-08-26 H. Lundbeck A/S Verfahren zur Herstellung von gereinigtem Citalopram
TR200200018T1 (tr) * 2000-12-28 2002-06-21 H. Lundbeck A/S Saf sitalopram hazırlanması için yöntem.
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
WO2002060886A1 (en) * 2001-01-30 2002-08-08 Orion Corporation, Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
JP2004529883A (ja) * 2001-02-22 2004-09-30 ナトコ ファーマ リミテッド シタロプラムの調製方法
GB0105627D0 (en) * 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
CZ20032567A3 (en) * 2001-03-09 2004-04-14 Ranbaxy Laboratories Limited Process for the preparation of citalopram
PL367480A1 (en) * 2001-05-01 2005-02-21 H.Lundbeck A/S The use of enantiomeric pure escitalopram
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IN192057B (no) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
MEP2108A (xx) * 2001-07-31 2010-02-10 Lundbeck & Co As H Kristalni sastav koji sadrži escitalopram
EP1288211A1 (en) * 2001-08-28 2003-03-05 Sekhsaria Chemicals Ltd. Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US6967259B2 (en) * 2001-09-24 2005-11-22 Pharmachem Technologies Limited Process for the preparation of Citalopram intermediate
ES2666188T3 (es) * 2001-10-12 2018-05-03 Azevan Pharmaceuticals, Inc. Antagonistas del v1a de vasopresina beta-lactámicos
IN192863B (no) * 2001-11-13 2004-05-22 Ranbaxy Lab Ltd
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
WO2003057132A2 (en) * 2002-01-07 2003-07-17 Sun Pharmaceutical Industries Limited Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
GB2387596B (en) * 2002-02-27 2004-02-11 Matrix Lab Ltd Process
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
KR100903841B1 (ko) * 2002-03-27 2009-06-25 반도 카가쿠 가부시키가이샤 신규의 1,3,5-트리스(아릴아미노)벤젠류
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
PE20040991A1 (es) * 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
WO2004016602A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited Process for the preparation of high purity citalopram and its pharmaceutically acceptable salts
GB2385051B (en) * 2002-08-29 2003-12-24 Max India Ltd Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
JP4658613B2 (ja) * 2002-12-23 2011-03-23 ハー・ルンドベック・アクチエゼルスカベット 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法
WO2004065375A1 (en) * 2003-01-17 2004-08-05 Natco Pharma Limited Processes for the preparation of escitalopram and its precursor
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
ITMI20030479A1 (it) * 2003-03-13 2004-09-14 Adorkem Technology S P A Procedimento per la preparazione di un ciano-isobenzofurano.
US7019153B2 (en) * 2003-06-10 2006-03-28 Sun Pharmaceutical Industries Limited Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
ITFI20030202A1 (it) * 2003-07-28 2005-01-29 Synteco Spa Processo per la preparazione di derivati del
SI1668014T1 (sl) * 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
WO2005042473A1 (en) * 2003-10-28 2005-05-12 Wockhardt Limited Improved process for the manufacture of citalopram hydrobromide
EP1506963B1 (en) * 2003-10-28 2005-04-13 Adorkem Technology SpA Method for the preparation of citalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP1708790B1 (en) * 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
WO2005077927A1 (en) * 2004-02-16 2005-08-25 Jubilant Organosys Limited One pot synthesis of citalopram from 5-cyanophthalide
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) * 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006021971A2 (en) 2004-08-23 2006-03-02 Sun Pharmaceutical Industries Limited 'process for preparation of citalopram and enantiomers'
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
WO2006103550A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Processes for the preparation of citalopram and its intermediate 5-aminophthalide
US20060258739A1 (en) * 2005-04-22 2006-11-16 Wyeth Dihydrobenzofuran derivatives and uses therof
PE20061319A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
AU2006239922A1 (en) 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
MX2007012883A (es) 2005-04-22 2007-12-10 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
TWI347942B (en) 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
AU2006269231A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
JP5328349B2 (ja) 2005-07-19 2013-10-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN101309924A (zh) * 2005-11-14 2008-11-19 H.隆德贝克有限公司 依地普仑的制备方法
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
WO2008036678A2 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP4927497B2 (ja) * 2006-10-25 2012-05-09 株式会社シスコ 無湿乾燥用ホッパー装置
CN100457747C (zh) * 2006-11-21 2009-02-04 浙江大学 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
WO2008086483A2 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
ATE534639T1 (de) 2007-04-23 2011-12-15 Synthon Bv Verfahren zur lösung von citalopram
NZ580738A (en) * 2007-05-18 2012-02-24 Cipla Ltd Process for the preparation of escitalopram
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US8022232B2 (en) * 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20100087664A1 (en) * 2008-10-07 2010-04-08 Ravindra Vedantham Preparation of citalopram and salts thereof
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
CN107007596A (zh) 2010-07-01 2017-08-04 阿泽凡药物公司 用于治疗创伤后应激障碍的方法
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
WO2013110313A1 (en) * 2012-01-23 2013-08-01 H. Lundbeck A/S Selective allosteric modulators of the serotonin transporter
MY184878A (en) 2014-03-28 2021-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
EP4091634A1 (en) 2016-03-10 2022-11-23 Janssen Pharmaceutica NV Methods of treating depression using orexin-2 receptor antagonists
US11628160B2 (en) 2017-09-15 2023-04-18 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (no) * 1965-03-18

Also Published As

Publication number Publication date
NO770109L (no) 1977-07-15
US4136193A (en) 1979-01-23
ZA7757B (en) 1977-11-30
DK13177A (da) 1977-07-15
NO1996001I1 (no) 1996-01-05
DE2657013C2 (de) 1985-11-14
BE850401A (fr) 1977-07-14
JPS52105162A (en) 1977-09-03
IE44055B1 (en) 1981-07-29
AU509445B2 (en) 1980-05-15
DK143275C (da) 1982-01-18
NL192451C (nl) 1997-08-04
CA1094087A (en) 1981-01-20
AT359488B (de) 1980-11-10
NL7700244A (nl) 1977-07-18
IE44055L (en) 1977-07-14
ATA947276A (de) 1980-04-15
NL192451B (nl) 1997-04-01
NL970031I1 (nl) 1997-10-01
JPS6135986B2 (no) 1986-08-15
NZ183001A (en) 1978-06-02
FI63754B (fi) 1983-04-29
CH626886A5 (no) 1981-12-15
CH632259A5 (de) 1982-09-30
SE7614201L (sv) 1977-07-15
FI63754C (fi) 1983-08-10
CH632258A5 (de) 1982-09-30
FR2338271B1 (no) 1982-11-05
NO147243B (no) 1982-11-22
SE429551B (sv) 1983-09-12
NL970031I2 (nl) 1997-10-01
DK143275B (da) 1981-08-03
DE2657013A1 (de) 1977-07-28
FR2338271A1 (fr) 1977-08-12
FI770073A7 (no) 1977-07-15
GB1526331A (en) 1978-09-27
ES454980A1 (es) 1978-04-01
AU2107377A (en) 1978-07-13

Similar Documents

Publication Publication Date Title
NO147243C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater
NO151411C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-aryloksy-2-hydroksy-3-alkylenaminopropan-derivater
NO151321C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater
NO151463C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolinderivater
NO149586C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive polypeptider
NO148453C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive spirohydantoinderivater
NO800881L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater
NO144848C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 4-hydroksyfenylalkanolamin-derivater
NO148777C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive antrakinon-derivater
NO149065C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater
NO145842C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive indolizinderivater
NO150044C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrazol-derivater
NO149313C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO145951C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolinderivater
NO149037C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO148488C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive acyl-benzimidazol-2-derivater
NO148291C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive basisk substituerte teofyllinderivater
NO148454C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidin-dionderivater
NO145163C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive antitumorglykosider
NO146710C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylpiperazinderivater
NO143903C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-fluorpyrimidin-4-on-derivater
NO152172C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive spiro-kinolyl-hydantoin-derivater
NO152556C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive antracen-biskarbonylhydrazoner
NO146600C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolderivater
NO147273C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive cykloheksadien-derivater